Abstract
The efficacy of vonoprazan-based dual and triple therapy vs. lansoprazole-based triple therapy in the treatment of H. pylori infection was largely consistent regardless of age, sex, race, ethnicity, BMI, alcohol intake, smoking status, and study drug compliance.